Broken String Biosciences, a cell and gene therapy developer, has appointed Steve Becker as its Chief Commercial Officer.
Steve will guide the expansion of the company’s commercial operations while implementing a market strategy for its next generation sequencing (NGS)- based DNA break-mapping platform INDUCE-seq.
Broken String has been strongly focused on expanding its global footprint and boosting its revenue growth since the close of its USD $15m Series A funding; to achieve this, the company has appointed several high-profile executives.
Steve will determine and implement the commercialisation strategy of Broken String’s INDUCE-seq for the future, while also working to extend the technology’s capabilities beyond gene editing.
He will also lead the global sales and marketing teams and technical support operations.
Steve has more than 30 years’ experience managing teams in the biopharmaceutical industry, and has worked in both small startups and multi-national organisations.
He joins Broken String from Thermo Fisher Scientific, where he led the licensing and commercial supply channel for the Genetic Sciences and Clinical Oncology NGS divisions, responsible for building commercial partnerships and managing large contract deals to expand the company’s global customer base.
Prior to this, he held executive level positions at Quest Diagnostics, Athena Diagnostics, Inc. and RainDance Technologies, in addition to leadership roles at Agilent Technologies and GE Healthcare.
Felix Dobbs, CEO of Broken String Biosciences, said: “We’re delighted that Steve is joining us to lead the Company’s commercial activities based out of Boston MA. As we enter our next stage of commercial growth and focus on establishing broad adoption of the INDUCE-seq platform, Steve’s support will be pivotal in executing the successful launch of our commercial offering, as well as establishing strong partnerships with leading academic and industry players in the genomics and cell & gene therapy markets.”
